glecaprevir Inhibitors
1 drugsAbout glecaprevir
Glecaprevir is a drug target for Hepatitis C, inhibiting a crucial protein required for viral replication and disrupting the HCV lifecycle.
As a viral protein, glecaprevir is targeted to disrupt viral replication rather than based on human genetics; there is currently no genetic evidence data available.
Glecaprevir is the target of one FDA-approved drug, MAVYRET, a small molecule therapy developed by AbbVie for infectious disease.
Top glecaprevir Drugs
AbbVie is the only company with an approved drug targeting glecaprevir.
The market is highly concentrated, indicating potential entry barriers for new competitors.
glecaprevir Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets glecaprevir, using small molecule modality.
The single modality suggests opportunities for exploring alternative therapeutic approaches.
glecaprevir Clinical Trials 34 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on glecaprevir. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 1 | 100% |
| Phase 2 | 6 | 5 | 0 | 1 | 100% |
| Phase 3 | 13 | 13 | 0 | 0 | 100% |
| Phase 4 | 12 | 5 | 6 | 1 | 45% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
glecaprevir Drug Approval Timeline (2017 - 2017)
The first and only drug, MAVYRET, was approved in 2017.
The approval timeline suggests potential saturation, but also opportunity for next-generation therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 17 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on glecaprevir. A trial counts if an approved drug acting on glecaprevir is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.